Convalescent plasma does not benefit high-risk COVID-19 outpatients with early symptoms, study shows

By | August 19, 2021
The final results of the Clinical Trial of COVID-19 Convalescent Plasma in Outpatients (C3PO) demonstrate that COVID-19 convalescent plasma did not prevent disease progression in a high-risk group of outpatients with COVID-19, when administered within the first week of their symptoms.